European bank of induced pluripotent stem cells

Title	European bank of induced pluripotent stem cells
Acronym	EBiSC
Website	http://www.ebisc.org/
Start date	2014-01-01
End date	2016-12-31
Sponsor	Innovative Medicines Initiative (IMI)

Associated cell lines

Publications

Fatima A et al. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2011;28(4):579-92.
Fatima A et al. The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients. PloS one. 2013;8(12):e83005.
Shao K et al. Induced pluripotent mesenchymal stromal cell clones retain donor-derived differences in DNA methylation profiles. Molecular therapy : the journal of the American Society of Gene Therapy. 2013 Jan;21(1):240-50.
Koch CM et al. Pluripotent stem cells escape from senescence-associated DNA methylation changes. Genome research. 2013 Feb;23(2):248-59.
Zhang XH et al. Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. Cell calcium. 2013 Aug;54(2):57-70.
Frobel J et al. Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem cell reports. 2014 Sep 9;3(3):414-22.
De Sousa PA et al. Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) - the Hot Start experience. Stem cell research. 2017 Apr;20:105-114.

Project Description

A consortium of 26 partners has been formed to establish the “European Bank for induced pluripotent Stem Cells” (EBiSC) with support from the IMI. The EBISC iPS cell bank will act as a central storage and distribution facility for human iPS cells, to be used by researchers across academia and industry in the study of disease and the development of new treatments for them.